Inst. Cat. Doncologia-H Duran I Reynals

Barcelona 8908

2 studies enrolling now · 8 studies all time

What they study most

Carcinoma, Non-small-Cell Lung, Hematological Malignancies, Multiple Myeloma, Squamous Cell Carcinoma of Head and Neck

Studies at this site

• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer — Recruiting now
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer — Recruiting now
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma — Running, not enrolling
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens — Completed
• Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab — Stopped early
• A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment — Completed